Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study.

Sava, Mihaela; Sommer, Gregor; Daikeler, Thomas; Woischnig, Anne-Kathrin; Martinez, Aurelien E; Leuzinger, Karoline; Hirsch, Hans H.; Erlanger, Tobias; Wiencierz, Andrea; Bassetti, Stefano; Tamm, Michael; Tschudin-Sutter, Sarah; Stoeckle, Marcel; Pargger, Hans; Siegemund, Martin; Boss, Renate; Zimmer, Gert; Vu, Diem-Lan; Kaiser, Laurent; Dell-Kuster, Salome; ... (2021). Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study. Swiss medical weekly, 151(w20550), w20550. EMH Media 10.4414/smw.2021.20550

Preview

Text Zimmer_Gert_Ninety-day_outcome_COVID-19_tocilizumab_smw_2021_20550.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (2MB) | Preview

OBJECTIVES

Patients with severe COVID-19 may be at risk of longer term sequelae. Long-term clinical, immunological, pulmonary and radiological outcomes of patients treated with anti-inflammatory drugs are lacking.

METHODS

In this single-centre prospective cohort study, we assessed 90-day clinical, immunological, pulmonary and radiological outcomes of hospitalised patients with severe COVID-19 treated with tocilizumab from March 2020 to May 2020. Criteria for tocilizumab administration were oxygen saturation <93%, respiratory rate >30/min, C-reactive protein levels >75 mg/l, extensive area of ground-glass opacities or progression on computed tomography (CT). Descriptive analyses were performed using StataIC 16.

RESULTS

Between March 2020 and May 2020, 50 (27%) of 186 hospitalised patients had severe COVID-19 and were treated with tocilizumab. Of these, 52% were hospitalised on the intensive care unit (ICU) and 12% died. Eleven (22%) patients developed at least one microbiologically confirmed super-infection, of which 91% occurred on ICU. Median duration of hospitalisation was 15 days (interquartile range [IQR] 10–24) with 24 days (IQR 14–32) in ICU patients and 10 days (IQR 7–15) in non-ICU patients. At day 90, 41 of 44 survivors (93%) were outpatients. No long-term adverse events or late-onset infections were identified after acute hospital care. High SARS-CoV-2 antibody titres were found in all but one patient, who was pretreated with rituximab. Pulmonary function tests showed no obstructive patterns, but restrictive patterns in two (5.7%) and impaired diffusion capacities for carbon monoxide in 11 (31%) of 35 patients, which predominated in prior ICU patients. Twenty-one of 35 (60%) CT-scans at day 90 showed residual abnormalities, with similar distributions between prior ICU and non-ICU patients.

CONCLUSIONS

In this cohort of severe COVID-19 patients, no tocilizumab-related long-term adverse events or late-onset infections were identified. Although chest CT abnormalities were highly prevalent at day 90, the majority of patients showed normal lung function.

TRIAL REGISTRATION

ClinicalTrials.gov NCT04351503.

Interest & Impact

Downloads

56 since deposited on 18 Nov 2021
33 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item